BLPH:NSD-Bellerophon Therapeutics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 10.17

Change

-0.22 (-2.12)%

Market Cap

USD 0.10B

Volume

0.03M

Average Target Price

USD 24.50 (+140.90%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its products include INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 2 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; that has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that is in Phase II dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension, pulmonary hypertension associated with pulmonary edema from high altitude sickness, and COVID-19 patients. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-09-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

+3.58 (+1.36%)

USD68.76B 34.32 27.50
REGN Regeneron Pharmaceuticals, Inc

+15.81 (+2.85%)

USD59.12B 21.90 16.92
SGEN Seattle Genetics, Inc

+3.12 (+1.74%)

USD31.48B N/A N/A
MRNA Moderna, Inc

-0.54 (-0.78%)

USD27.33B N/A N/A
GMAB Genmab A/S

-0.35 (-0.91%)

USD25.18B 27.12 3.06
BGNE BeiGene, Ltd

-2.27 (-0.84%)

USD25.05B N/A N/A
RPRX Royalty Pharma plc

+1.13 (+2.78%)

USD24.64B 35.72 9.73
ALXN Alexion Pharmaceuticals, Inc

+2.77 (+2.48%)

USD24.49B 30.43 27.52
IMMU Immunomedics, Inc

-0.36 (-0.42%)

USD19.70B N/A N/A
INCY Incyte Corporation

+1.54 (+1.80%)

USD18.67B 47.64 35.20

ETFs Containing BLPH

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 2,805.71% 100% A+ 100% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 2,805.71% 100% A+ 100% A+
Trailing 12 Months  
Capital Gain 1,700.00% 99% A+ 99% A+
Dividend Return N/A N/A N/A N/A N/A
Total Return 1,700.00% 99% A+ 99% A+
Trailing 5 Years  
Capital Gain 160.77% 87% B+ 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 160.77% 87% B+ 85% B
Average Annual (5 Year Horizon)  
Capital Gain 265.40% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 265.40% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 678.08% N/A N/A N/A N/A
Risk Adjusted Return 39.14% N/A N/A N/A N/A
Market Capitalization 0.10B 26% F 29% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 5.29 55% F 84% B
Price/Book Ratio 1.88 82% B- 55% F
Price / Cash Flow Ratio -7.63 59% F 78% C+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -52.90% 60% D- 23% F
Return on Invested Capital -420.89% 3% F 1% F
Return on Assets -27.38% 49% F 14% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 4.35 49% F 38% F
Short Percent 4.30% 64% D 44% F
Beta -0.49 97% A+ 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.